key: cord-0713439-id9hk9hb authors: Fenwick, Craig; Turelli, Priscilla; Perez, Laurent; Pellaton, Céline; Esteves-Leuenberger, Line; Farina, Alex; Campos, Jérémy; Lana, Erica; Fiscalini, Flurin; Raclot, Charlène; Pojer, Florence; Lau, Kelvin; Davide, Demurtas; Descatoire, Marc; Joo, Victor S.; Foglierini, Mathilde; Noto, Alessandra; Abdelnabi, Rana; Foo, Caroline S.; Vangeel, Laura; Neyts, Johan; Du, Wenjuan; Bosch, Berend-Jan; Veldman, Geertruida; Leyssen, Pieter; Thiel, Volker; LeGrand, Roger; Lévy, Yves; Trono, Didier; Pantaleo, Giuseppe title: A highly potent antibody effective against SARS-CoV-2 variants of concern date: 2021-09-21 journal: Cell Rep DOI: 10.1016/j.celrep.2021.109814 sha: 28915e7c57efad0fb98a536792148650d64ffba5 doc_id: 713439 cord_uid: id9hk9hb Control of the ongoing SARS-CoV-2 pandemic is endangered by the emergence of viral variants with increased transmission efficiency, resistance to marketed therapeutic antibodies and reduced sensitivity to vaccine-induced immunity. Here, we screen B cells from COVID-19 donors and identify P5C3, a highly potent and broadly neutralizing monoclonal antibody with picomolar neutralizing activity against all SARS-CoV-2 variants of concern (VOC) identified to date. Structural characterization of P5C3 Fab in complex with the Spike demonstrates a neutralizing activity defined by a large buried surface area, highly overlapping with the receptor-binding domain (RBD) surface necessary for ACE2 interaction. We further demonstrate that P5C3 shows complete prophylactic protection in the SARS-CoV-2 infected hamster challenge model. These results indicate that P5C3 opens exciting perspectives either as a prophylactic agent in immunocompromised individuals with poor response to vaccination or as combination therapy in SARS-CoV-2-infected individuals. Identification of P5C3, a highly potent SARS-CoV-2 neutralizing antibody 104 In the present study, we screened a cohort of 40 hospitalized COVID-19 patients for the 105 presence of anti-Spike antibodies between 7 and 30 days after symptoms onset. At ~3 months (Figure S1A ). 115 Given that emerging VOCs contain mutations in and around the Spike RBD that confer 116 resistance to potent neutralizing mAbs (Korber et al., 2020; Ozono et al., 2021) , we next 117 examined the binding properties of our ten prioritized mAbs to Spike derivatives with 118 mutations and/or deletions found in VOCs. REGN1033, REGN10987 and S309, three mAbs 119 used in the clinic, were tested in parallel as benchmarks ( Figure 1A and Figure S1B) . In was prioritized for further characterization and development. 132 As a first step, competitive Spike binding studies were performed with the ACE2 protein and 133 therapeutic antibodies known to recognize distinct epitopes on the RBD. P5C3 competed for 134 RBD binding with ACE2 and REGN10933 but had a non-competitive binding profile (<20% 135 blocking) with REGN10987 or S309 mAbs ( Figure 1B) . Of note, this analysis additionally 136 revealed that through stearic hindrance or binding induced conformational change in RBD, 137 REGN10987 is at least partially competitive with both REGN10933 and S309 mAbs for RBD 138 binding. 139 We then measured the ability of P5C3 and benchmark mAbs to neutralize 2019-nCOV SARS- (Figure 2A and 2B) . It (Hoffmann et al., 2021) . 165 We also used in these experiments a modified form of P5C3 containing the so-called LS Wang et al., 2021b). REGN10987 and S309 both displayed broad neutralization potential 179 against these variants, but EC 80 values of REGN10987 were 5.6-to 9.5-fold less potent than 180 measured for P5C3 LS against the 2019-nCoV and D614G viruses and S309 was 28-to 177-181 fold less potent against all tested viruses ( Figure 3B ). 182 Thus, the combination of binding studies with neutralization assays performed with 183 pseudotyped-or live virus-based assays singled out P5C3 as a mAb with unmatched potency 184 against the broad range of Spike mutations found in circulating VOC, prompting us to 185 perform additional studies aimed at characterizing how it interacts with its antigenic target. Figure S4 ). 198 First, we characterized the overall interaction between the P5C3 paratope and the viral Spike 199 trimer. We confirmed that its target epitope overlaps with the ACE2 receptor-binding site of Moreover, we could determine that P5C3 binds its epitope through five of its (Figure S4E and S5C) . In the CDR H3, P95, G100, S100a, C100b, D100d and F100f 214 make multiple contacts with the RBD thumb region (residues 475-489; Figure S4E Interestingly, the mAb binding epitope also partially covers the antiparallel β5, β6 strands of 221 Spike (residues 451-456 and 491-495), a domain that should not be subjected to the 222 development of resistance mutations owing to its essential folding function ( Figure S5B ). 223 To understand further why P5C3 binding is not affected by mutations harbored by SARS- Figure S5D ). 235 We went on to compare the P5C3 binding mode to that of leader ACE2 blocking mAb In sum, we report the discovery of P5C3, a highly potent SARS-CoV-2 Class I neutralizing and hydrophobic contacts with the RBD core, suggest that mutations to escape P5C3 binding 287 will invariably impact either affinity for ACE2 or folding properties of the RBD, both 288 resulting in either reduced overall infectivity or an important fitness cost for the virus. As 289 such, it is predicted that direct mutations in RBD at the contact site with P5C3 will invariably 290 impact the affinity for ACE2, resulting in a reduced overall infectivity and fitness of the virus. The proportion of the population receiving COVID-19 vaccines is continually increasing in 322 many countries with a corresponding reduced rate of infections and hospitalizations. However, preliminary reports indicate that pre-existing natural immunity against the wild type 462 Reagent generated in this study will be made available on request, but we may require a 463 payment and/or a completed Materials Transfer Agreement, which allows the use of the 464 antibodies for non-commercial purposes but not their disclosure to third parties. Life Technologies). Cells were cultured at 37 °C, 5% CO2 at 95% air atmosphere. Cov2 Spike (Genbank NC_045512 ) was modified using QuickChange mutagenesis to 658 generate mutants with D614G alone or in combination with A222V, N439K, S477N and 659 E484K/N501Y and K417N/E484K/N501Y as previously described (Fenwick et al., 2021b) . Approximately 2 million of particles were used to generate four Ab initio volumes were 706 generated, with one class of 585 005 particles revealing an S-trimer complexed with 3 Fabs. The map of interest was processed by non-uniform refinement with C1 symmetry to generate 708 a map with a resolution of 3.5Å. Next, to improve the Fab RBD interface resolution, a local The authors worked to ensure diversity in experimental samples through the selection of the cell lines. 789 One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in 790 science. The author list of this paper includes contributors from the location where the research was 791 conducted who participated in the data collection, design, analysis, and/or interpretation of the work. 792 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 mAb concentration (g/ml) 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 mAb concentration (g/ml) 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 mAb concentration (g/ml) COVID-19 and the impact of social determinants of health PHENIX: a comprehensive Python-based system for 797 macromolecular structure solution EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy Structures of Human Antibodies 804 Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape 808 seen with individual antibodies STAT2 signaling restricts viral dissemination but 811 drives severe pneumonia in SARS-CoV-2 infected hamsters SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 Resistance of SARS-CoV-2 variants to neutralization by monoclonal 818 and serum-derived polyclonal antibodies MolProbity: all-atom structure validation for 821 macromolecular crystallography Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. 825 Nature Protocol and Reagents for Pseudotyping Lentiviral 828 Particles with SARS-CoV-2 Spike Protein for Neutralization Assays Estimated transmissibility and impact of 831 SARS-CoV-2 lineage B.1.1.7 in England Features and development of Coot Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses 836 Impact the Estimates of Infections in Population-Based Seroprevalence Studies T-cell 839 exhaustion in HIV infection A multiplexed high-throughput neutralization assay reveals a lack of activity 842 against multiple variants after SARS-CoV-2 infection Multiple SARS-CoV-2 variants escape 846 neutralization by vaccine-induced humoral immunity A single injection of anti-HIV-1 antibodies protects against 849 repeated SHIV challenges UCSF ChimeraX: Meeting modern challenges in visualization and analysis Studies in humanized mice and convalescent humans yield a SARS-CoV-2 855 antibody cocktail Studies in humanized mice and convalescent humans yield a SARS-CoV-2 858 antibody cocktail SARS-CoV-2 mutations acquired in mink reduce 861 antibody-mediated neutralization LY-CoV555, a rapidly isolated potent 864 neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection Favipiravir at high doses has potent antiviral 868 activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity Tracking Changes in SARS-CoV-2 Spike: Evidence that 872 D614G Increases Infectivity of the COVID-19 Virus Longitudinal Isolation of Potent Near-Germline SARS-CoV-876 2-Neutralizing Antibodies from COVID-19 Patients Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Automated electron microscope tomography using robust prediction of 882 specimen movements A simplified 884 workflow for monoclonal antibody sequencing The Risk and Impact of COVID-887 19 Pandemic on Immunosuppressed Patients: Cancer, HIV, and Solid Organ Transplant Recipients SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-891 binding affinity UCSF Chimera--a visualization system for exploratory research and analysis Mapping Neutralizing and Immunodominant Sites on 897 the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology cryoSPARC: algorithms for rapid 900 unsupervised cryo-EM structure determination An Engineered Antibody with Broad Protective Efficacy 903 in Murine Models of SARS and COVID-19 Convergent antibody responses to SARS-CoV-2 in convalescent 906 individuals Optimal determination of particle orientation, absolute 908 hand, and contrast loss in single-particle electron cryomicroscopy Arkalagud 911 A single-dose 912 live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate A 915 human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen Prospective mapping of viral mutations that escape antibodies used to treat 922 COVID-19 Attributes and predictors of long COVID Rapid reconstruction of SARS-CoV-2 using a synthetic 928 genomics platform Circulating SARS-CoV-2 spike N439K variants 931 maintain fitness while evading antibody-mediated immunity Ultrapotent human antibodies protect against SARS-CoV-2 935 challenge via multiple mechanisms An efficient method to make human monoclonal 938 antibodies from memory B cells: potent neutralization of SARS coronavirus Assessing transmissibility of SARS-CoV-2 lineage B.1.1 Antigenicity of the SARS-CoV-2 Spike Glycoprotein A human monoclonal antibody blocking SARS-948 CoV-2 infection Antibodies with potent and broad neutralizing activity against antigenically 951 diverse and highly transmissible SARS-CoV-2 variants Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 Enhanced receptor binding of SARS-CoV-2 through networks of 956 hydrogen-bonding and hydrophobic interactions REGN-COV2, a Neutralizing Antibody Cocktail Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Enhanced antibody half-life improves in vivo activity Evidence of escape of SARS-976 CoV-2 variant B.1.351 from natural and vaccine induced sera Cell A pneumonia outbreak associated with a new coronavirus of probable bat origin